Brief: Akeso Says (Ivonescimab Injection) Obtained Nmpa's Marketing Approval In China
24/05/2024 09:11
May 24 (Reuters) - Akeso Inc 9926.HK :
* (IVONESCIMAB INJECTION) OBTAINED NMPA'S MARKETING APPROVAL
IN
CHINA
Further company coverage: 9926.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Akeso
See all newsBrief: Akeso Announces Summit Therapeutics And Ecog-Acrin Cancer Research Group Enter Into Phase Ii/Iii Clinical Trial Collaboration To Evaluate Ivonescimab In First-Line Biliary Tract Cancer
Factbox: Major drugmakers turn to China for licensing deals
HK-listed Akeso drops most in nearly three months on discounted share sale
Brief: Akeso To Place 20 Million New Shares At HK$97.76 Per Share
Factbox: Major drugmakers turn to China for licensing deals